Vaccine News and Research

Latest Vaccine News and Research

Prellis Externalized Human Immune System produces human antibodies against SARS-Cov2

Prellis Biologics, Inc. today announced that it has generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus.

20 May 2020

No SARS-COV-2 among young children in Belgium attending daycare, report researchers

A study conducted by researchers in Belgium has found no evidence to support concerns that asymptomatic young children may be a source of severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) transmission.

19 May 2020

X-ray experiments demonstrate a new way to block the entry of SARS-CoV-2

As scientists across the globe race to develop a vaccine against SARS-CoV-2, the coronavirus that causes COVID-19, an international team led by Davide Corti at Vir Biotechnology and David Veesler at the University of Washington has been working around the clock on a complementary approach - identifying neutralizing antibodies that could be used as a preventative treatment or as a post-exposure therapy.

19 May 2020

New capsules are critical for addressing the rapidly changing bacteria, says expert

Vaccines that protect people from infection by Streptococcus pneumonia, which kills up to 1 million children every year worldwide, train the immune system to recognize the pathogen's thick sugar capsule.

19 May 2020

New animal model for COVID-19

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to ravage the world, scientists are frantically searching for a vaccine or new drug that will effectively counter the lethal effects of the virus that leads to COVID-19 disease.

19 May 2020

New vaccine appears to be highly protective against Ebola infection in mice

As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

18 May 2020

Human immune repertoire may not commonly produce cross-neutralizing antibodies to coronaviruses

Patients infected with either severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 produce antibodies that bind to the other coronavirus, but the cross-reactive antibodies are not cross protective, at least in cell-culture experiments, researchers report May 17 in the journal Cell Reports.

18 May 2020

People with Hepatitis D have up to three times the risk of developing fatal liver cancer

Of all the hepatitis viruses, D is the most poorly known. This small virus, which can only infect people already infected with Hepatitis B, has so far been little studied.

18 May 2020

Local variations in climate not likely to drive early COVID-19 pandemic

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal Science.

18 May 2020

Novel insights on SARS-CoV-2 cell entry may inform further vaccine and treatment development

A research group from Harvard Medical School reported two cryo-electron microscopy structures derived from a single preparation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in their paper available on the preprint server bioRxiv. Understanding the nuances of prefusion and postfusion conformations shed light on viral cell entry and may, in turn, guide the development of vaccines and drugs.

18 May 2020

University of Valencia files patent application for COVID-19 vaccine

The University of Valencia has filed a patent application for a vaccine candidate against COVID-19, developed by a research team from the Department of Microbiology

18 May 2020

Drugmakers tout COVID-19 vaccines to refurbish their public image

Johnson & Johnson researchers working on a vaccine against the coronavirus are "just like the heroes in the hospitals" fighting to save patients, J&J CEO Alex Gorsky said on the "Today" show a few weeks ago.

18 May 2020

People infected with hepatitis D are more prone to hepatocellular carcinoma

Of all the hepatitis viruses, D is the most poorly known.This small virus, which can only infect people already infected with Hepatitis B, has so far been little studied.

18 May 2020

Avacta's SARS-COV-2 neutralizing Affimer reagents show therapeutic potential for COVID-19

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway.

From Avacta Life Sciences Ltd. 18 May 2020

COVID-19 clinical trials show positive early results, says GlobalData

With the number of COVID-19 cases and deaths increasing with each passing day, the need for a therapeutic or a vaccine for the pandemic intensifies.

18 May 2020

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.

18 May 2020

Oxford University vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

As the world continues to grapple with the coronavirus pandemic, many scientists, institutions, and pharmaceutical companies are working hard to develop an effective vaccine.

18 May 2020

Staggered local re-openings could be the best COVID-19 exit strategy

When a new infectious disease appears, the lack of an effective treatment or vaccine strategy often results in the application of non-pharmacological interventions (NPIs) or containment measures, including testing for infection, tracing contacts, and isolating potential sources of infection.

17 May 2020

Inadequate vaccine and epidemic control in the US

A new paper published on the preprint server medRxiv* in May 2020 shows that vaccination must be combined with nonpharmacological interventions (NPIs) to achieve rapid and effective control of the ongoing pandemic.

17 May 2020

Researchers investigate safety of convalescent plasma for COVID-19

The current pandemic of COVID-19 seems to be slowing down in various parts of the world, but is far from controlled, as incidence rates rise in new regions. In the absence of an effective vaccine or therapeutic drug, scientists have relied on supportive medical care to treat the sick.

17 May 2020